Within months of the onset of the worldwide COVID-19 pandemic, the Berkeley Lights Platform was used to identify lead molecules that bind and block the interaction of SARS-CoV-2 virus proteins with their human cell receptors.
Using the Opto™ Viral Neutralization workflow, scientists at Vanderbilt University were able to functionally characterize tens of thousands of individual B cells recovered from patient samples in a single day. This allowed them to deliver sequences of confirmed neutralizing antibodies to downstream manufacturing partners in 18 days.
These antibodies are now part of AstraZeneca’s Phase III clinical trial.
Clone tens of thousands of B cells into pico-liter sized NanoPen™ chambers on a microfluidic chip.
Perform multiple fluorescence-based assays on the same cell to determine antigen specificity, cross-reactivity, and function.
Simplify downstream sequence recovery with on-chip mRNA capture and cDNA synthesis.
Recover sequences of high-value, functionally characterized lead candidates.
Learn how antibody discovery is changing in today’s therapeutic space. Case studies presented by Abveris highlight accelerated development of next-generation antibody therapeutics.
Learn how to use blocking and binding assays and the Opto Viral Neutralization 1.0 workflow to identify cross-reactive antibodies that may have broad neutralization capacity across the coronavirus family.
Dr. James Rothman, Nobel Laureate hosts an in-depth discussion with distinguished guests, Dr. Jennitte Stevens from Amgen, Dr. Gregory Bleck from Catalent-Biologics, and Dr. Trent Munro from the University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.